Halozyme Therapeutics | HALO - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Amarin USD 131.06M 3.6M 2026-03
Amgen USD 12.04B 2.91B 2026-03
Baxter International USD 2.02B 51M 2026-03
Cara Therapeutics USD 20.73M 684K 2025-12
Cytokinetics USD 129.84M 7.32M 2026-03
DBV Technologies USD 194.17M 124.33M 2025-12
Eli Lilly USD 5.28B 1.99B 2026-03
Esperion Therapeutics USD 156.16M 11.69M 2026-03
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Intrexon USD 9.34M 1.77M 2024-06
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
MannKind USD 52.83M 22.05M 2026-03
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Pfizer USD 1.7B 561M 2026-03
Rigel Pharmaceuticals USD 48.53M 4.87M 2025-09
United Therapeutics USD 1.28B 277.4M 2026-03
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12